Sentences with phrase «left ventricular ejection»

The key to a traditional policy approval will be a recent echocardiogram, treadmill stress test, or cardiac catheterization showing that the heart is not overly enlarged, and the left ventricular ejection fraction (LVEF) is still within acceptable levels.

• increased left ventricular ejection fraction (11, 12) • improved exercise tolerance (12, 13, 14) • increased cardiac output (15) • better prognosis for patients with chronic heart failure (16) • lowered markers of oxidative stress (17, 18)

Whereas left ventricular ejection fraction and ventricle size were not measurably affected by ADF, the observed changes suggest caution in the human application of regimens using frequent fasting (51).

A transthoracic echocardiogram demonstrated an inferior wall motion abnormality and a left ventricular ejection fraction of 35 - 45 % (see Figures 2 - 6).

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criteria

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

There was an improvement in left ventricular ejection fraction and in myocardial function.

The researchers measured various factors including finger arterial blood pressure, heart rate, left ventricular ejection time, and cardiac output.

All runners with decreased left ventricular ejection fraction (LVEF), a measure of cardiac pumping efficiency, after the race compared with baseline underwent a third MRI study after three months of rest to check whether it had reversed.

Although the primary endpoint was not met, a statistically significant 4 percent improvement was seen in a secondary endpoint, left ventricular ejection fraction — a measure of how much blood is being pumped out of the left ventricle — in patients whose STEMIs involved the front wall of the left ventricle (the heart's main pumping chamber), he said.

Contrary to popular practice, a measure of the heart's pumping function known as «left ventricular ejection fraction» is not associated with the long - term outcomes of hospitalized heart failure patients, a UCLA - led study of Medicare patients has found.

Participants with symptomatic heart failure and a left ventricular ejection fraction of 45 percent or more (normal or near normal contractions) were randomized to receive either spironolactone (15 to 45 milligrams daily) or matching placebo, and were followed for an average of nearly 3.3 years.

In patients with the implantable device, the heart got smaller, the left ventricular diastolic volume decreased significantly and the heart became stronger, with significant improvements in left ventricular ejection fraction.

Iron deficiency is present in approximately 50 percent of patients with heart failure with reduced left ventricular ejection fraction (HFrEF; ejection fraction: a measure of how well the left ventricle of the heart pumps with each contraction) and is associated with reduced functional capacity, poorer quality of life, and increased mortality.

The standard test for risk assessment in relation to life - threatening cardiac rhythm disturbances is currently the left ventricular ejection fraction, which represents a measure of the heart's function and measures the volume of the beat in relation to the overall volume of blood in the ventricle.

Not exact matches

Patients treated with processed autologous adipose - derived regenerative cells (ADRCs) injected into the heart muscle demonstrated symptomatic improvement and a trend towards lower rates of heart failure hospitalizations and angina, despite no improvement in left ventricle ejection fraction (LVEF) or ventricular volumes.